Current Report Filing (8-k)
January 28 2021 - 9:26AM
Edgar (US Regulatory)
0000887247
false
0000887247
2021-01-28
2021-01-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
January 28, 2021
___________________
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
11682 El Camino Real, Suite 300
San Diego, CA
|
92130
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (858) 997-2400
(Former name or Former Address, if Changed
Since Last Report.)
___________________
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Exchange Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock
|
|
ADMP
|
|
NASDAQ
Capital Market
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
On January 28, 2021, Adamis Pharmaceuticals
Corporation (“Adamis” or the “Company”) issued a press release announcing that the Company, in collaboration
with the Human Immune Monitoring Center at Stanford University, has conducted a study to investigate the effects of Tempol, the
Company’s investigational drug candidate, on immune cells from COVID-19 patients, and announcing preliminary data from the
study. A copy of the Company’s press release is attached hereto as Exhibit 99.1 is incorporated into this item by reference.
Forward Looking Statements
This
Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets
or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future
results of operations, including, but not limited to the following statements: the company’s beliefs concerning the safety
and effectiveness of Tempol; the timing of funding for, or commencement or completion of, any studies or trials relating to Tempol;
the availability of, and the company’s success in applying for and obtaining, government or other funding for studies or
trials relating to Tempol or the timing or amount of any such funding; the results of any future studies or trials that the company
may conduct relating to Tempol; the company’s ability to commercialize the product candidates described in this Report, itself
or through commercialization partners; and other statements concerning our future operations and activities. These statements are
only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis' actual results to
be materially different from the results anticipated by such forward-looking statements. There are no assurances whether final
data produced from the study discussed in the press release attached as an exhibit to this Report will be consistent with the preliminary
data or the extent to which Tempol will be shown to decrease cytokines from stimulated cells from COVID-19 patients. There
can be no assurances regarding the outcome of trials or studies relating to Tempol; regarding the timing or the outcome of any
applications or requests that we may submit for government or other funding for studies or trials relating to Tempol; concerning
the timing or outcome of any such studies or trials; or that Tempol will be found to be safe and effective in the treatment of
COVID-19 or any other indication. In addition, forward-looking statements concerning our anticipated future activities assume that
we are able to obtain sufficient funding to support such activities and continue our operations and planned activities. As discussed
in our filings with the Securities and Exchange Commission, we will require additional funding, and there are no assurances
that such funding will be available if required. We cannot assess the impact of each factor on our business or the extent to which
any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking
statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks
only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update
or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising
after the date of this Report. Certain of these risks and additional risks, uncertainties, and other factors are described in greater
detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December
31, 2019 and subsequent filings with the SEC,
which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site
at http://www.sec.gov. Except to the extent required by law, any forward-looking statements in this press release speak
only as the date of this press release, and Adamis expressly disclaims any obligation to update any forward-looking statements.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
|
Dated: January 28, 2021
|
By:
|
/s/ Robert O. Hopkins
|
|
Name:
|
Robert O. Hopkins
|
|
Title:
|
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Sep 2023 to Sep 2024